See Recent Shionogi-Sponsored Congress Presentations
Congresses
As part of our commitment to addressing unmet medical needs, Shionogi continues to investigate approved products and pipeline compounds. Shionogi presents its research at major congress events globally.
The content contained herein is for your information only. No reproduction, alteration, or distribution of this information is permitted. Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Select a congress event or filter to view available congress presentations.
You Are Viewing Presentations
Safety, tolerability, and pharmacokinetics of single- and multiple-dose cefiderocol in hospitalized pediatric patients: Results of the PEDI-CEFI phase 2 study
Safety, tolerability, and pharmacokinetics of single- and multiple-dose cefiderocol in hospitalized pediatric patients: Results of the PEDI-CEFI phase 2 study
The impact of xeruborbactam on in vitro activity of cefiderocol against a challenge panel of Acinetobacter baumannii enriched in isolates with increased cefiderocol MICs
The impact of xeruborbactam on in vitro activity of cefiderocol against a challenge panel of Acinetobacter baumannii enriched in isolates with increased cefiderocol MICs
The impact of xeruborbactam on in vitro activity of cefiderocol against a challenge panel of Enterobacterales enriched with isolates with increased cefiderocol MICs
The impact of xeruborbactam on in vitro activity of cefiderocol against a challenge panel of Enterobacterales enriched with isolates with increased cefiderocol MICs
The oral protease inhibitor ensitrelvir reduces SARS-CoV-2 transmission in a hamster model
The oral protease inhibitor ensitrelvir reduces SARS-CoV-2 transmission in a hamster model
The time to return to work in healthcare workers with COVID-19 infection treated with ensitrelvir, a novel oral inhibitor of 3C-like protease of SARS-CoV-2
The time to return to work in healthcare workers with COVID-19 infection treated with ensitrelvir, a novel oral inhibitor of 3C-like protease of SARS-CoV-2
Therapeutic effect of delayed treatment with a second-generation 3CL protease inhibitor S-892216 in hamsters infected with SARS-CoV-2
Therapeutic effect of delayed treatment with a second-generation 3CL protease inhibitor S-892216 in hamsters infected with SARS-CoV-2
You Are Viewing Congress Locations
ESCMID 2025
CROI 2025
SCCM 2025
IDWeek 2024
NACFC 2024
IAS 2024
ESCMID 2024
SCCM 2024
IDWeek 2023
CHEST 2023
ESWI 2023
ISSX 2023
PAGE 2023
